Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IVVD | 8-K | neutral | 6/10 | Invivyd appointed Chairman Marc Elia as CEO, replacing the CFO who had been serving as principal executive officer. The | Sep 1, 2026 |
| AZN | 6-K | neutral | 5/10 | AstraZeneca completed its previously announced exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy | Sep 1, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received EU approval fo | Sep 1, 2026 |
| INDP | 8-K | bearish | 5/10 | Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabli | Sep 1, 2026 |
| AZN | 6-K | neutral | 3/10 | AstraZeneca's wholly owned subsidiary, AstraZeneca Finance LLC, has admitted EUR 2.55 billion in four tranches of fixed- | Sep 1, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced the initiation of Phase IIa of its Phase I/IIa trial for CMND-100 in Alcohol Use Disorder, | Sep 1, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences announced its participation in five investor conferences in September 2026, including a fireside ch | Sep 1, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune | Sep 1, 2026 |
| CDT | 8-K | bearish | 6/10 | CDT Equity Inc. appointed James Bligh as CEO, replacing Dr. Andrew Regan who resigned immediately. Bligh, who also remai | Sep 1, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of MI | Sep 1, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced positive Phase III SANOVO trial results showing Tagrisso plus Orpathys achieved a statistically si | Sep 1, 2026 |
| UPB | 8-K | bullish | 7/10 | Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP following productive | Sep 1, 2026 |
| MSLE | 6-K | neutral | 2/10 | Satellos Bioscience announced management participation in two upcoming investor conferences in September 2026: the Canto | Sep 1, 2026 |
| BTAI | 8-K | bearish | 9/10 | BioXcel Therapeutics filed for Chapter 11 bankruptcy on August 27, 2026, and this 8-K reports two terminal events: (1) e | Sep 1, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on September 1, 2026, solely to submit an exhibit (Exhibit 99.1) for an applicati | Sep 1, 2026 |
| NVS | 6-K | bullish | 7/10 | Novartis announced positive Phase III topline results for remibrutinib in relapsing multiple sclerosis (RMS). The REMODE | Sep 1, 2026 |
| OCGN | PRESS-RELEASE | bullish | 7/10 | Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) and highlighted | Sep 1, 2026 |
| MEDP | CLUSTER | neutral | 2/10 | Three Medpace insiders (CEO, CFO, Director) sold a combined $4.91M in open-market sales over a 7-day window. However, th | Sep 1, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined ~$1.44M of TRDA shares over five days, representi | Sep 1, 2026 |
| PMVP | PRESS-RELEASE | bearish | 8/10 | PMV Pharmaceuticals priced a dilutive underwritten public offering of 22,055,000 common shares plus pre-funded warrants | Aug 31, 2026 |
| FENC | CLUSTER | neutral | 4/10 | Two Fennec Pharmaceuticals executives (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day window, re | Aug 31, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two MPM BioVentures funds (10% owners) sold a combined $383K in TRDA shares over a 7-day window, representing ~0.14% of | Aug 31, 2026 |
| SLGL | INSIDER-BUY | bullish | 6/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, purchased $2.43M of SLGL shares in open-market transaction | Aug 31, 2026 |
| ONCO | S-1/A | bearish | 8/10 | Onconetix filed Amendment No. 1 to its S-1 registration statement to register the resale of up to 100,000,000 shares of | Aug 31, 2026 |
| PMVP | 8-K | bullish | 7/10 | PMV Pharmaceuticals announced updated interim Phase 2 data for rezatapopt in platinum-resistant/refractory ovarian cance | Aug 31, 2026 |
| ASND | 6-K | neutral | 6/10 | Ascendis Pharma announced a binding term sheet for a global settlement and license agreement with BioMarin, resolving al | Aug 31, 2026 |
| WLKP | 8-K | neutral | 2/10 | Westlake Chemical Partners LP appointed Tommy E. Darby as Vice President and Chief Accounting Officer of its general par | Aug 31, 2026 |
| JAZZ | 144 | neutral | 2/10 | Director Ted W. Love filed a Form 144 notice of intent to sell 1,527 shares of Jazz Pharmaceuticals common stock, valued | Aug 31, 2026 |
| KZIA | PRESS-RELEASE | bearish | 6/10 | Kazia Therapeutics closed an oversubscribed, tranched public offering generating approximately $40 million in upfront gr | Aug 31, 2026 |
| WLK | 8-K | neutral | 2/10 | Westlake Corp appointed Tommy E. Darby as Vice President, Chief Accounting Officer, effective August 31, 2026. The incum | Aug 31, 2026 |